Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc.

NNASDAQ:LTGO
12.60
USD
-0.51
(-3.89%)
-2.12EPS
1.11BMarket Cap
Mar 03Next Earn
Latigo Biotherapeutics, Inc.
NASDAQ:LTGO
(Nasdaq Stock Market)

Recent

price

12.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2024
2025
TTM
USD
- -
- -
- -
Revenue per Share
-1.39
-2.48
-2.12
Basic EPS, GAAP
-1.16
-2.22
-2.04
Free Cash Flow per Basic Share
- -
- -
- -
Dividend per Share
-2.15
-3.85
5.94
Book Value per Share
-2.15
-3.85
5.94
Tangible Book Value per Share
44
44
51
Basic Weighted Avg Shares
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Operating Margin (%)
- -
- -
- -
Depreciation Expense
-61
-109
-107
Net Income, GAAP
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
7
55
392
Working Capital
- -
- -
- -
LT Debt
-130
-232
394
Total Equity
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
31
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
66
Market Capitalization
- -
- -
1,107

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
47
59
406
Cash, Cash Equivalents & STI
42
55
401
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
14
52
14
Payables & Accruals
13
12
10
ST Debt
1
31
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
78.76%
Free Cash Flow
- -
- -
91.45%
Net Income, GAAP
- -
- -
78.43%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-1.39
2025
-0.48
-0.59
-0.56
-0.62
-2.48
2026
-0.52
-0.43
-0.55
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Latigo Biotherapeutics Inc. is a clinical-stage biotechnology company focused on the discovery and development of targeted therapies for solid tumor cancers, with a emphasis on novel oncology platforms and drug candidates aimed at tumor-specific biology and enhanced therapeutic indices. Latigo operates in the U.S. market with research and development activities primarily centered in its corporate headquarters and laboratories in the United States, leveraging collaborations with academic and industry partners to advance preclinical and clinical programs. Main products and services: discovery and development of oncology therapeutics; preclinical and clinical candidate generation; target validation and biomarker development; formulation, manufacturing process development for early-stage clinical supply; translational research and pharmacology studies; strategic collaborations and out-licensing of programs to pharmaceutical partners; regulatory strategy support and Clinical Trial Planning; scientific advisory and outsourced research services. Latest major company changes: enters collaborations and strategic alliances with industry partners to advance pipeline programs; completes or participates in financing rounds to fund R&D activities; pursues potential acquisitions or asset acquisitions to broaden portfolio; launches or expands new product candidates within its oncology platform; undergoes corporate reorganizations or leadership changes to optimize strategic focus; implements operational scaling or facility expansions to support pipeline progression. Additional context: Industry and segments include biotechnology, oncology therapeutics, small-molecule and potential biologic modalities; target markets include global pharmaceutical collaborators, research institutions, and later-stage development partners; geographic footprint primarily United States with potential interactions in international clinical trial sites; founding year and headquarters location tied to its corporate registration in the United States; may have subsidiaries or parent company relationships as part of corporate structuring.

Company News

  • Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Stock Has Consensus Price Target of $52.25 According to Analysts

  • Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

  • Latigo Biotherapeutics Announces CEO Transition to Support the Company's Next Phase of Growth

  • Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November

  • Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It

  • Latigo Biotherapeutics (NASDAQ:LTGO) Hits New 12-Month Low – Here’s Why

  • Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO)

  • Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

  • Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public

  • Latigo Biotherapeutics (NASDAQ:LTGO) Director James Tananbaum Buys 140,000 Shares

  • Latigo Biotherapeutics (NASDAQ:LTGO) Major Shareholder Foresite Capital Management V, Acquires 140,000 Shares

  • Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain